OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS

M&A Transactions

M&A Transaction Chart

Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.

Week ended 02/09/2024

Week ended 02/09/2024

This Section is Only Available to Higher Tier Memberships

Please Purchase a Premium or Enterprise membership to see more.

M&A Transactions Commentary

Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.

Week ended 02/09/2024

  • The Largest M&A Deal of the Week:
  • On February 6, 2024, Aurora Cannabis (ACB: Nasdaq), The fifth-largest Canadian LP by market cap, completed its acquisition of the remaining 90% stake in Indica Industries Pty Ltd. in a transaction valued at $32.62M.
  • Consideration for the transaction was $26.45M in stock and cash of $6.17M.
  • Indica is the partner of Canadian licensed producer Med Releaf.
  • Another important M&A Deal
  • On February 6, 2024, Curaleaf International, a subsidiary of Curaleaf Holdings (CURA: TSX)(CURLF: OTCQX), announced its expansion into Poland with the acquisition of Can4Med, a pharmaceutical wholesaler specializing in cannabis medications.
  • The acquisition follows new rules by Poland’s National Agriculture Support Center, streamlining the permitting process for farmers.
  • No financial terms of the acquisition were disclosed.

Week ended 02/09/2024

This is the MA basic

Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.